Alipogene tiparvovec

Drug Profile

Alipogene tiparvovec

Alternative Names: AMT-010; AMT-011; AMT-11; Glybera; LPL gene therapy - AMT

Latest Information Update: 01 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amsterdam Molecular Therapeutics
  • Developer uniQure
  • Class Antihyperlipidaemics; Gene therapies
  • Mechanism of Action Gene transference; Lipoprotein lipase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type I
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperlipoproteinaemia type I
  • No development reported Hyperlipoproteinaemia type V

Most Recent Events

  • 20 Jul 2017 UniQure Biopharma and Chiesi Farmaceutici terminates a phase II trial for Hyperlipoproteinaemia type I prior to enrolment in USA and Canada, as uniQure has decided not to renew the marketing authorization of glybera in the European Union (NCT02904772)
  • 20 Apr 2017 uniQure will not seek for Marketing Authorization renewal for alipogene tiparvovec in European Union due to economic considerations
  • 13 Sep 2016 UniQure Biopharma and Chiesi Farmaceutici plans a phase II trial for Hyperlipoproteinaemia type I in USA and Canada (NCT02904772)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top